Download PDF
Hamostaseologie 1996; 16(03): 180-187
DOI: 10.1055/s-0038-1656654
Übersichtsarbeiten/Review Articles
Schattauer GmbH

Erworbene Faktor-V-Inhibitoren

P. Knöbl
1   Universitätsklinik für Innere Medizin I, Abteilung für Hämatologie und Hämostaseo-logie (Leiter: Prof. Dr. K. Lechner), Universität Wien
,
B. Tribl
1   Universitätsklinik für Innere Medizin I, Abteilung für Hämatologie und Hämostaseo-logie (Leiter: Prof. Dr. K. Lechner), Universität Wien
,
K. Lechner
1   Universitätsklinik für Innere Medizin I, Abteilung für Hämatologie und Hämostaseo-logie (Leiter: Prof. Dr. K. Lechner), Universität Wien
› Author Affiliations
Further Information

Publication History

Publication Date:
23 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Zusammenfassung

Erworbene Faktor-V-Inhibitoren sind eine seltene Gerinnungsstörung. Weltweit wurden bisher 72 Fälle publiziert. Die Inzidenz scheint jedoch zuzunehmen, was wahrscheinlich auf den gehäuften Einsatz von Fibrinklebern zurückzuführen ist. Diese Metaanalyse untersucht die prädiponierenden Faktoren, die Pathogenese, diagnostische Methoden, klinisches Erscheinungsbild, therapeutische Möglichkeiten und den langfristigen Verlauf aller bisher publizierten Fälle von Faktor-V-Inhibitoren.

Schlüsselwörter

Faktor-V-Inhibitoren - erworbene Gerinnungsstörungen
 

  • LITERATUR

  • 1 Abe T, Kazama M, Itokazu K. et al. A case of sigmoid cancer who acquired factor V inhibitor producibility and treated with factor VIII inhibitor bypassing activity preparation FEIBA - with bibliographic review. Rinsho Ketsueki 1980; 21: 1664-73
    PubMedGoogle Scholar
  • 2 Ballester OF, Morelli G, Saba H. l, Foulis P. An IgG, time dependent, acquired factor V (FV) inhibitor. Blood 1990; 76: 411a
    PubMedGoogle Scholar
  • 3 Berruyer M, Amiral J, Ffrench P. et al. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors. J Thorac Cardiovasc Surg 1993; 105: 892-7
    PubMedGoogle Scholar
  • 4 Blecker SM, Williams AC. Postextraction bleeding in a patient with an acquired circulating anticoagulant against factor V. Oral Surg 1971; 32: 538-42
    CrossrefPubMedGoogle Scholar
  • 5 Brandt JT, Britton A, Kraut E. A spontaneous factor V inhibitor with unexpected laboratory features. Arch Pathol Lab Med 1986; 110: 224-7
    PubMedGoogle Scholar
  • 6 Bryning K, Leslie J. Factor V inhibitor and bullous pemphigoid. Br Med J 1977; 2: 677-8
    CrossrefPubMedGoogle Scholar
  • 7 Buclin T, Schmidt PM, Hauert J. et al. Inhibiteur acquis du facteur V traité par immuno-globulines intraveineuses. Schweiz Med Wochenschr 1992; 122: 1968-70
    PubMedGoogle Scholar
  • 8 Chediak J, Ashenhurst JB, Garlick I, Desser RK. Successful managment of bleeding in a patient with factor V inhibitor by platelet transfusion. Blood 1980; 56: 835-41
    PubMedGoogle Scholar
  • 9 Chiu HC, Koneti Rao A, Beckett C, Colman RW. Immune complexes containing factor V in a patient with an acquired neutralizing antibody. Blood 1985; 65: 810-8
    PubMedGoogle Scholar
  • 10 Cmolik BL, Spero JA, Magovern GJ, Clark RE. Redo cardiac surgery: late bleeding complications from topical thrombin-indu-ced factor V deficiency. J Thorac Cardiovasc Surg 1993; 105: 222-8
    PubMedGoogle Scholar
  • 11 Chong LL, Wong YC. A case of factor V inhibitor. Am J Hematol 1985; 19: 395-9
    CrossrefPubMedGoogle Scholar
  • 12 Coots MC, Muhleman AF, Glueck H. l. Hemorrhagic death associated with a high titer factor V inhibitor. Am J Hematol 1978; 4: 193-206
    CrossrefPubMedGoogle Scholar
  • 13 Crowell EB. Observations of a factor V inhibitor. Br J Hematol 1975; 29: 397-404
    CrossrefPubMedGoogle Scholar
  • 14 Diem K, Mayr W, Sautner T. et al. Anti-HLA antibody removal by IgG immunoapheresis in highly sensitized renal transplant recipients. J Am Soc Nephrol 1995; 6: 1080a
    PubMedGoogle Scholar
  • 15 DuMoulin A, Müller-Derlich J, Bieber F. et al. Antibody based immunoadsorption as a therapeutic means. Blood Purif 1993; 11: 145-9
    CrossrefPubMedGoogle Scholar
  • 16 Feinstein D. l. Acquired inhibitors of factor V. Thromb Haemost 1978; 39: 663-74
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Feinstein D. l, Rapaport S. l, Chong MMY. Factor V inhibitor: report of a case, with comments on a possible effect of streptomycin. Ann Int Med 1973; 78: 385-8
    CrossrefPubMedGoogle Scholar
  • 18 Feinstein D. l, Rapaport S. l, McGehee WG, Patch MJ. Factor V anticoagulants: clinical, biochemical and immunological observations. J Clin Invest 1970; 49: 1578-88
    CrossrefPubMedGoogle Scholar
  • 19 Ferguson JH, Johnston CL, Howell DA. A circulating inhibitor (Anti-AcG) specific for the labile factor V of the blood clotting system. Blood 1958; 13: 382-97
    PubMedGoogle Scholar
  • 20 Fratantoni JC, Hilgartner M, Nachman RL. Nature of the defect in congenital factor V deficiency. Study in a patient with an acquired circulating anticoagulant. Blood 1972; 39: 751-8
    PubMedGoogle Scholar
  • 21 George S, Nagabhushana MS, Cyran EM. Coagulopathy due to an acquired factor V inhibitor and subsequently thrombosis. Am J Hematol 1995; 49: 98-100
    PubMedGoogle Scholar
  • 22 Gordon B, Haire W, Duggan M. et al. Factor V inhibitor developing after liver transplantation in a 3-year-old child. Pediatrics 1991; 88: 156-9
    PubMedGoogle Scholar
  • 23 Grace CS, Wolf P. A high titer circulating inhibitor of human factor V: clinical, biochemical and immunological features and its treatment by plasmapheresis. Thromb Diath Haemorrh 1975; 34: 322
    PubMedGoogle Scholar
  • 24 Grigg AP, Dauer R, Thurlow PJ. Bleeding due to an acquired inhibitor of platelet associated factor V. Aust N Z J Med 1989; 19: 310-4
    CrossrefPubMedGoogle Scholar
  • 25 Handley DA, Duncan EM. A circulating anticoagulant specific for factor V. Pathology 1969; 1: 265-72
    CrossrefPubMedGoogle Scholar
  • 26 Hörder MH. Isolierter Faktor-V-Mangel bedingt durch einen spezifischen Hemmkörper. Acta Haematol 1955; 13: 235-7
    CrossrefPubMedGoogle Scholar
  • 27 Hörder MH, Sokal G. Inhibitorstudien bei familiärem Faktor-V-Mangel. Acta Haematol 1955; 14: 65-8
    CrossrefPubMedGoogle Scholar
  • 28 Hurtubise PE, Coots MC, Jacob DJ. et al. A monoclonal IgG4 (λ) with factor V inhibitory activity. J Immunol 1979; 122: 2119-21
    PubMedGoogle Scholar
  • 29 Jobard J, Pourcher N, Gratecos N, Bayle J. Syndrome hemorrhagique du à un anticoagulant circulant antifacteur V. Presse Med 1983; 12: 1606
    PubMedGoogle Scholar
  • 30 Kapur A, Kelsey PR, Isaaks PET. Factor V inhibitor in thrombosis. Am J Hematol 1993; 42: 384-8
    CrossrefPubMedGoogle Scholar
  • 31 Kaspar CK. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72
    PubMedGoogle Scholar
  • 32 Knöbl P, Derfler K, Korninger L. et al. Elimination of acquired factor VIII antibodies by extracorporal antibody-based immunoadsorption (Ig-Therasorb). Thromb Haemost 1995; 74: 1035-8
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Koyama T, Saito T, Kusano T, Hirosawa S. Factor V inhibitor associated with Sjögren's syndrome. Br J Haematol 1995; 89: 893-6 24
    CrossrefPubMedGoogle Scholar
  • 34 Kuto M, Izuchi Y, Deguchi K. et al. An inhibitor against factor V occurring postoperatively in a case of pancreatic cancer. Acta Haematol Japon 1981; 44: 938-50
    PubMedGoogle Scholar
  • 35 Lane TA, Shapiro SS, Burka ER. Factor V antibody and disseminated intravascular coagulation. Ann Int Med 1978; 89: 182-5
    CrossrefPubMedGoogle Scholar
  • 36 Lazarchick J, Wolff CM, Pepkowitz SH. et al. Factor V inhibitor associated with immune complex formation. Arch Pathol Lab Med 1986; 110: 448-51
    PubMedGoogle Scholar
  • 37 Lerolle D, Dreyer-Dufer C, Allain JP. Anticoagulant circulant specifique du facteur V. Nouv Presse Med 1981; 10: 1483-7
    PubMedGoogle Scholar
  • 38 Lopez VR, Pflugshaupt R, Bütler R. A specific inhibitor of human clotting factor V. Acta Haematol (Basel) 1968; 40: 275-85
    CrossrefPubMedGoogle Scholar
  • 39 Massignon D, Roullit S, Espinouse D, Coeur P. Apparition d'un anticoagulant circulant antifacteur V après intervention chirurgicale. Ann Fr Anesth Reanim 1989; 8: 70-2
    CrossrefPubMedGoogle Scholar
  • 40 Mazzucconi MG, Solinas S, Chistolini A. et al. Inhibitor of factor V in severe factor V congenital deficiency. A case report. Nouv Rev Fr Hematol 1985; 27: 303-5
    PubMedGoogle Scholar
  • 41 Muntean W, Zenz W, Finding K. et al. Inhibitor to factor V after exposure to fibrin sealant during cardiac surgery in a two-year-old child. Acta Paediatr 1994; 83: 84-7
    PubMedGoogle Scholar
  • 42 Nesheim ME, Nichols WL, Cole TL. et al. Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest 1986; 77: 405-15
    CrossrefPubMedGoogle Scholar
  • 43 Nichols WL, Daniels TM, Fisher PK. et al. Inhibitor of coagulation factor V and thrombin associated with surgical use of topical bovine thrombin or fibrin glue. Blood 1991; 78 (Suppl. 01) 63
    PubMedGoogle Scholar
  • 44 Nilsson IM, Hedner U, Ekberg M, Denne-berg T. A circulating anticoagulant against factor V. Acta Med Scand 1974; 195: 72-9
    PubMedGoogle Scholar
  • 45 Okajima A, Horii J, Nasu K. et al. Factor V inhibitor with double cancer. Rinsho Ketsueki 1989; 30: 514-9
    PubMedGoogle Scholar
  • 46 Onoura CA, Lindenbaum J, Nosseel HL. Massive hemorrhage associated with circulating antibodies to factor V. Am J Med Sci 1973; 265: 407-17
    CrossrefPubMedGoogle Scholar
  • 47 Ortel TL, Quinn-Allen MA, Charles LA. et al. Characterisation of an acquired inhibitor to coagulation factor V. J Clin Invest 1992; 90: 2340-7
    CrossrefPubMedGoogle Scholar
  • 48 Rapaport S. l, Ziveln A, Minow RA. et al. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol 1992; 97: 84-91
    CrossrefPubMedGoogle Scholar
  • 49 Smid WM, de Wolf JTM, Nijland JH. et al. Severe bleeding caused by an inhibitor to coagulation factor V: a case report. Blood Coag Fibrinolys 1994; 5: 133-7
    PubMedGoogle Scholar
  • 50 Spero JA. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases. J Neurosurg 1993; 78: 817-20
    CrossrefPubMedGoogle Scholar
  • 51 Stefanini M, Dameshek W. The Hemorrhagic Disorders: A Clinical and Therapeutical Approach. New York: Grund & Stratton 1955; 368
    PubMedGoogle Scholar
  • 52 Stenbjerg S, Husted S, Myging K. A circulating factor V inhibitor: possible side effect of treatment with streptomycin. Scand J Hematol 1975; 14: 280-5
    PubMedGoogle Scholar
  • 53 Stricker RB, Lane PK, Leffert JD. et al. Development of antithrombin antibodies following surgery in patients with prosthetic cardiac valves. Blood 1988; 1375-80
    PubMedGoogle Scholar
  • 54 Taillan B, Fuzibet JG, Vinti H. et al. Factor V inhibitor in celiac disease. Am J Med 1989; 87: 360
    CrossrefPubMedGoogle Scholar
  • 55 Takase T, Fujimura Y, Mikami S. et al. Factor V inhibitor developing in a patient with pulmonary tuberculosis. Rinsho Ketsueki 1980; 21: 1038-46
    PubMedGoogle Scholar
  • 56 Thomas F, Robert A, Luquel L. et al. Syndrome hemorragique mortel après mithramycine. La Presse Med 1989; 18: 182
    PubMedGoogle Scholar
  • 57 Tribl B, Knöbl P, Derfler K. et al. Rapid elimination of a high titer spontaneous factor V antibody by extracorporal antibody-based immunoadsorption and immunosuppression. Ann Haematol 1995; 71: 199-203
    CrossrefPubMedGoogle Scholar
  • 58 Tsang PWK, Naiman SC. Development of antibodies to bovine thrombin and to other coagulation factors in three patients after cardiac surgery. Blood 1991; 78 (Suppl. 01) 65a
    PubMedGoogle Scholar
  • 59 Vickars LM, Coupland RW, Naiman SC. The response of an acquired factor V inhibitor to activated factor IX concentrate. Transfusion 1985; 25: 51-3
    CrossrefPubMedGoogle Scholar
  • 60 Zehnder JL, Leung LLK. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990; 76: 2011-6
    PubMedGoogle Scholar